Pharming Group N.V. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated March 13, 2025, reports preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. Pharming Group N.V. is a global biopharmaceutical company focused on rare diseases, primarily commercializing RUCONEST® (for HAE) and Joenja® (leniolisib for APDS). The period marks a leadership transition with the appointment of Fabrice Chouraqui as CEO and the completion of the acquisition of Abliva AB.
Key Financial Metrics
| Metric | 4Q 2024 | 4Q 2023 | Full Year 2024 | Full Year 2023 |
|---|---|---|---|---|
| Total Revenues | $92.7M | $81.2M | $297.2M | $245.3M |
| Gross Profit | $80.5M | $74.1M | $261.8M | $220.1M |
| Operating Profit (Loss) | $6.7M | $1.1M | ($8.6M) | ($5.4M) |
| Net Profit (Loss) | $3.7M | ($3.1M) | ($11.0M) | ($10.5M) |
| Cash & Marketable Securities | $169.4M | $215.0M | $169.4M | $215.0M |
| Convertible Bonds | $82.4M | $138.4M | $82.4M | $138.4M |
Revenue Breakdown (Full Year 2024): RUCONEST® generated $252.2M (11% growth); Joenja® generated $45.0M (147% growth). The U.S. market accounted for 98% of RUCONEST® revenue and 90% of Joenja® revenue.
Material Changes vs. Prior Period
- Revenue Growth: Full-year revenue increased 21%, exceeding the prior guidance range of $280M–$295M. Q4 revenue grew 14% year-over-year.
- Profitability: The company returned to operating profitability in Q4 ($6.7M) and generated positive net cash flows from operations for the second consecutive quarter. However, the full-year operating loss widened to $8.6M compared to $5.4M in 2023, largely due to the absence of a one-time $21.3M Priority Review Voucher (PRV) sale in 2023.
- Acquisition: Completed the acquisition of Abliva AB for approximately $66.1M, adding the KL1333 asset for mitochondrial diseases. This was funded internally without external financing.
- Leadership: Fabrice Chouraqui succeeded Sijmen de Vries as CEO effective March 4, 2025.
- One-Time Items: Q4 included $6.2M in one-off expenses, including a $5.1M impairment of a leased facility and $1.1M in acquisition-related fees.
Guidance, Outlook, and Risks
- 2025 Guidance: Total revenue expected between $315M and $335M (6%–13% growth). Operating expenses are projected not to exceed the prior year's pre-Abliva impact, plus an estimated $30M in Abliva-related expenses.
- Pipeline Progress:
- Joenja® (Leniolisib): Positive Phase III results in pediatric patients (ages 4–11); regulatory filings planned for Japan (mid-2025) and U.S. pediatric expansion (H2 2025). Two new Phase II trials initiated for additional Primary Immunodeficiencies (PIDs) and CVID.
- KL1333: Pivotal FALCON trial for mitochondrial diseases is ongoing; second wave of recruitment starting. Readout expected in 2027.
- Risks & Contingencies:
- Regulatory approvals for leniolisib in key markets (Japan, EU, Canada) remain pending.
- Success of VUS (Variant of Uncertain Significance) resolution programs is critical for expanding the APDS patient pool.
- Integration risks associated with the Abliva acquisition and the FALCON trial execution.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of RUCONEST® growth (9% Q4 increase) and the trajectory of Joenja® patient enrollment (96 paid patients in U.S. as of Dec 31, 2024).
- Acquisition Accounting: Confirm the allocation of the $66.1M Abliva purchase price and the impact of the $30M estimated 2025 operating expense increase on cash burn.
- Regulatory Milestones: Monitor the timeline for the Japan PMDA filing (mid-2025) and the U.S. pediatric submission (H2 2025) for leniolisib.
- Cash Position: Assess the $169.4M cash balance against the projected 2025 operating expenses and R&D investments, noting the recent convertible bond refinancing.
- One-Time Adjustments: Review the "like-for-like" operating loss comparison ($8.6M in 2024 vs. $16.2M in 2023 excluding PRV and milestone items) to understand core operational efficiency.